Over the past few years, considerable attention has been focused on carrageenan based bionanocomposites due to their multifaceted properties like biodegradability, biocompatibility, and nontoxicity. Moreover, these composites can be tailored according to the desired purpose by using different nanofillers. The role of ferromagnetic nanoparticles in drug delivery is also discussed here in detail. Moreover, this article also presents a short review of recent research on the different types of the carrageenan based bionanocomposites and applications.

The objective of the current study was to design and optimize prednisolone acetate-loaded chitosan nanoparticles (NPs) through design experts for ophthalmic drug delivery. Chitosan NPs were prepared by ionic gelation using sodium tripolyphosphate (TPP). The effects of variables, such as chitosan concentration, chitosan to TPP mass ratio (ch:TPP), and prednisolone concentration on particle size, zeta potential (ZP), and polydispersity index (PDI), were studied using a three-factor three-level central composite design (CCD), and optimum experimental conditions were determined using the desirability function combined response surface methodology (RSM). Quadratic and reduced quadratic polynomial models were generated to predict and evaluate the independent variables with respect to the dependent variables. The composition of the optimal formulation was determined to be a chitosan concentration of 0.26%, chitosan to TPP mass ratio of 6:1, and drug concentration with respect to chitosan mass of 8.11%. The optimized formulation showed a percentage entrapment efficiency (% EE) of 78.32%, mean particle size of 193.5, PDI of 0.219, ZP of 10.3 mV, and 86.15% cumulative drug release. The morphology of the NPs was found to be nearly spherical in shape by scanning electron microscopy (SEM). Differential scanning calorimetry (DSC) revealed successful loading of the drug in NPs, and FTIR confirmed polymer and drug compatibility.

Making nanoscale drug carriers could boost the bioavailability of medications that are slightly water soluble. One of the most promising approaches for enhancing the chemical stability and bioavailability of a variety of therapeutic medicines is liquid nanocrystal technology. This study aimed to prepare nanocrystals of mangiferin for sustained drug delivery and enhance the pharmacokinetic profile of the drug. The fractional factorial design (FFD) was used via a selection of independent and dependent variables. The selected factors were the concentration of mangiferin (A), hydroxypropyl methyl cellulose (HPMC) (B), pluronic acid (C), tween 80 (D), and the ratio of antisolvent to solvent (E). The selected responses were the particle size, polydispersity index (PDI), zeta potential, and entrapment efficiency. The nanocrystals were further evaluated for mangiferin release, release kinetics, Fourier transforms infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), X-ray diffraction (XRD), particle size, zeta potential, and scanning electron microscopy (SEM). The stability studies of developed nanocrystals were performed for 6 months and pharmacokinetics on albino rabbits. The value of entrapment efficiencies ranged from 23.98% to 86.23%. The percentage release of mangiferin varied from 62.45 to 99.02%. FTIR and DSC studies showed the stability of mangiferin in the nanocrystals. The particle size of the optimized formulation was almost 100 nm and −12 mV the value of the zeta potential. The results of stability studies showed that the nanocrystals of mangiferin were stable for a period of six months. The peak plasma concentration of mangiferin from nanocrystals and suspension of mangiferin were 412 and 367 ng/mL, respectively. The value of AUC_0−t of nanocrystals and suspension of mangiferin was 23,567.45 ± 10.876 and 18,976.12 ± 9.765 µg×h/mL, respectively, indicating that the nanocrystals of mangiferin showed greater availability of mangiferin compared to the suspension of the formulation. The developed nanocrystals showed a good release pattern of mangiferin, better stability studies, and enhanced the pharmacokinetics of the drug.

Gemcitabine (GC)-loaded chitosan nanoparticles were synthesized by ionic gelation method, and optimization was accomplished by Box–Behnken design based on particle size (PS), polydispersity index (PDI), zeta potential (ZP), and percent entrapment efficiency (% EE). The optimized formulation (OF) exhibited PS, PDI, ZP, and % EE to be 206.7 nm, 0.285, +27 mV, and 77.61%, respectively. Fourier transform infrared spectroscopy, X-ray diffraction analysis, and differential scanning calorimetry analyses confirmed GC’s stability in nanoparticles. The OF showed an initial rapid release of 61%, followed by a slower release, reaching 95.81% over 96 h. OF was studied on a PC-3 cell line to evaluate its effectiveness in treating prostate cancer, where it exhibited higher cytotoxicity (IC ₅₀ ∼3.06 ± 0.32 μg/ml) compared to pure GC (IC ₅₀ ∼4.11 ± 0.81 μg/ml). After oral administration in albino rabbits, the peak plasma concentrations ( C _max ) for GC solution and OF were 1,290 and 3,070 ng/ml, respectively. The time to reach maximum plasma concentration ( t _max ) was 1 h for GC solution and 6 h for OF. The half-life ( t _1/2 ) was 5.6 h for GC solution and 16.9 h for OF, indicating a prolonged half-life for OF. OF demonstrated an effective release pattern of GC, improved stability, enhanced pharmacokinetic profile, and higher toxicity compared to GC.

Frostbite is caused due to extreme vulnerability to cold, resulting in damage of deeper and superficial tissues alike. In this study, we report the anti‐inflammatory and wound‐healing properties of aqueous methanolic extract of Cuscuta reflexa (Cs.Cr) against contact frostbite. Thirty rats were divided into five groups including three treatment groups with increasing doses of Cs.Cr, a standard drug group receiving acetylsalicylic acid (ASA), and a metal bar‐induced frostbite group. Frostbite injury was induced by a 3 × 3.5 cm metal bar frozen up to ‐79°C on shaved skin for continuous 3 minutes. Wounded area percentages were recorded to measure the healing rate in response to Cs.Cr administration. Haematological parameters and malondialdehyde content were also noted. On treatment with Cs.Cr, the healing rate is drastically increased and lipid peroxidation product malondialdehyde was decreased in a dose‐dependent manner. Results were compared with frostbite and ASA (standard drug group). These results indicate that Cs.Cr possesses excellent wound‐healing properties against frostbite injury and can prove to be a prospective compound in such conditions.